BIOMAT Database Logo BIOMAT Database Logo

Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors. 2005

Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Center for AIDS Research, Stanford University, Stanford, CA, USA. mark.winters@stanford.edu

HIV-1 strains that possess a one or two amino acid insert between codons 102 and 103 of the reverse transcriptase (RT) gene were identified in three HIV-1-infected individuals. Each strain also had one or more known mutations associated with nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs). Recombinant viruses from these strains had reduced susceptibility to efavirenz and nevirapine, and homology modelling predicted a loss of binding contacts with efavirenz. Mutagenesis studies indicated that replication of insert-containing strains was dependent on RT gene mutations and polymorphisms that co-evolved with the insert. These results suggest that inserts in the NNRTI-binding pocket contribute to NNRTI resistance, but are tolerated only under specific genetic conditions.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000480 Alkynes Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenic Compounds,Alkyne,Acetylenes
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase

Related Publications

Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.
March 2005, AIDS (London, England),
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
June 2019, Journal of virology,
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Search for new non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-1 RT).
January 2002, Acta poloniae pharmaceutica,
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
January 2002, Current pharmaceutical design,
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
February 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy,
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
June 2003, AIDS (London, England),
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
June 2001, Journal of medicinal chemistry,
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
Mark A Winters, and Ron M Kagan, and Ladislau Kovari, and Peter N R Heseltine, and Thomas C Merigan
[HIV resistance to non-nucleoside reverse transcriptase inhibitors].
August 2006, Virologie (Montrouge, France),
Copied contents to your clipboard!